In simple terms, Applied Genetic Technologies Corporation has 67.632 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -97.902%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -51.738%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust -0.293% return, is a testament to Applied Genetic Technologies Corporation's adeptness in optimizing resource deployment. Applied Genetic Technologies Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.536%. Furthermore, the proficiency of Applied Genetic Technologies Corporation in capital utilization is underscored by a remarkable -1.035% return on capital employed.
Stock Prices
Applied Genetic Technologies Corporation's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.4125, while its low point bottomed out at $0.396. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Applied Genetic Technologies Corporation's stock market.
Company general description and statistics
Sector: Healthcare
Industry: Biotechnology
CEO:Ms. Susan Washer
Full-time employees:102
City:Alachua
Address:14193 Nw 119Th Terrace, Suite #10
IPO:2014-03-27
CIK:0001273636
Website:
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
